The effects of discontinuing cinacalcet at the time of kidney transplantation

Background. The calcimimetic, cinacalcet, is approved for treating secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) on dialysis. Biochemical profiles and clinical outcomes in patients discontinuing cinacalcet at kidney transplantation have not been previously descri...

Descripción completa

Detalles Bibliográficos
Autores principales: Jadoul, Michel, Baños, Ana, Zani, Valter J., Hercz, Gavril
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2010
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808133/
https://www.ncbi.nlm.nih.gov/pubmed/20090879
http://dx.doi.org/10.1093/ndtplus/sfp167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808133/
https://www.ncbi.nlm.nih.gov/pubmed/20090879
http://dx.doi.org/10.1093/ndtplus/sfp167

Ejemplares similares